Fortune, a global business magazine picked our company in the December editorial through an extended interview with our Founder and CEO, Filippo Surace.

“In 2014 we have started as a Technology Transfer Venture, today we evolved into an holding biotech platform fully devoted to the innovation in Life Sciences”

The article examines the route of the company from its debut to date successes with a view into its future goals:  starting from today and up to 2022, we plan to create 20-22 biotech spin-offs around orphan diseases, oncology and green-therapy with a key eye in personalized medicine.

Filippo Surace → https://www.linkedin.com/in/filipposurace/